Companies: Signant Health, Ametris, Archimed
Genstar-backed Signant Health Acquires Ametris: Implications for eCOA and Digital Outcome Measures
0% citation coverage2 regulatory sources
Signant Health, backed by Genstar Capital, has acquired Ametris (formerly ActiGraph) from Archimed, creating an integrated platform for electronic clinical outcome assessments (eCOA) and wearable-derived digital measures. The deal consolidates two key clinical trial technology providers, with implications for study design, data quality, and vendor consolidation.
Executive Summary
- Genstar-backed Signant Health acquires Ametris from Archimed, pairing eCOA tools with validated wearable sensors for an end-to-end evidence platform.
- The merger reduces vendor fragmentation for sponsors, potentially cutting integration costs and simplifying reconciliation between patient-reported and objective outcomes.
- Pharma BD teams should benchmark this combined offering against Medidata, IQVIA, and Clario, while monitoring for bundled pricing that could reshape trial budgets.
Market Impact
| Regulatory | medium |
|---|---|
| Commercial | medium |
| Competitive | high |
| Investment | medium |
Genstar-backed Signant Health Acquires Ametris: Implications for eCOA and Digital Outcome Measures
Signant Health, backed by Genstar Capital, has acquired Ametris (formerly ActiGraph) from Archimed, creating an integrated platform for electronic clinical outcome assessments (eCOA) and wearable-derived digital measures. The deal consolidates two key clinical trial technology providers, with implications for study design, data quality, and vendor consolidation.
Key Takeaways
- Genstar-backed Signant Health acquires Ametris from Archimed, pairing eCOA tools with validated wearable sensors for an end-to-end evidence platform.
- The merger reduces vendor fragmentation for sponsors, potentially cutting integration costs and simplifying reconciliation between patient-reported and objective outcomes.
- Pharma BD teams should benchmark this combined offering against Medidata, IQVIA, and Clario, while monitoring for bundled pricing that could reshape trial budgets.
The development
On June 1, 2026, Signant Health announced it had acquired Ametris, a global provider of digital health solutions specializing in wearable-derived outcome measures, from Archimed. Ametris was formerly known as ActiGraph before its acquisition by Archimed. The deal pairs Signant's electronic clinical outcome assessment (eCOA) tools with Ametris's validated wearable sensors, creating what the companies describe as an end-to-end platform for evidence generation in clinical trials. Ropes & Gray advised Signant Health on the transaction.
Jeremy Wyatt, CEO of Signant Health, framed the acquisition as a direct response to sponsor demand for unified data streams. "By bringing together industry-leading eCOA with validated, wearable-derived digital measures, we are removing a major source of complexity for sponsors who want to capture the full patient experience," Wyatt said in the announcement. Roger Smith, CEO of Ametris, echoed the sentiment, noting that the combined platform would allow researchers to "smoothly integrate patient-reported outcomes with continuous, objective sensor data."
What this deal means for pharma BD teams
For pharma strategy and business development teams, this acquisition signals a broader trend toward platform consolidation in clinical trial technology. Sponsors have long complained about the operational friction of stitching together separate eCOA and sensor data pipelines. The combined entity can now offer a single source for capturing both subjective patient reports and objective digital biomarkers, potentially slashing integration costs and data reconciliation efforts.
The deal also reshapes the competitive landscape. Signant Health now competes more directly with Medidata, IQVIA, and Clario, each of which has been building out its own decentralized clinical trial (DCT) toolkits. Teams should monitor how this acquisition affects pricing—bundled eCOA-plus-wearable offerings could either lower per-study costs or lock sponsors into broader platform commitments that complicate multi-vendor strategies.
Data standardization is another watchpoint. Ametris brings years of validation work on its actigraphy and digital monitoring endpoints, which have been used in hundreds of trials across CNS, respiratory, and oncology indications. If Signant standardizes these measures into its own platform architecture, it could accelerate the acceptance of digital endpoints by regulators, a long-standing hurdle for the industry. The FDA's 2023 guidance on digital health technologies emphasizes the need for validated sensor data in drug development, and this acquisition positions Signant to meet those standards more efficiently.
How will this affect study design flexibility?
Pharma teams designing complex trials should weigh the trade-offs of a consolidated platform. On one hand, a single vendor for eCOA and wearables can streamline site training, reduce the number of data transfer agreements, and simplify audit trails. On the other hand, sponsors may lose the ability to pick best-in-class point solutions for specific therapeutic areas—for example, a specialized actigraphy algorithm for Parkinson's disease or a proprietary sleep sensor for respiratory trials.
The acquisition also raises questions about interoperability. Signant Health will need to ensure that Ametris's sensor data formats align with the CDISC standards increasingly required by regulators for submission-ready datasets. If the integration is seamless, it could reduce the timeline from data collection to regulatory filing. If not, sponsors could face additional mapping work.
Frequently Asked Questions
What exactly did Signant Health acquire?
Signant Health acquired Ametris, a global digital health solutions provider formerly known as ActiGraph, from the healthcare investment firm Archimed. Ametris specializes in wearable sensors that capture objective outcome measures such as activity levels, sleep patterns, and gait analysis for use in clinical trials.
How will this acquisition affect clinical trial sponsors?
Sponsors can expect a more integrated approach to capturing patient-reported outcomes and sensor-derived digital endpoints within a single platform. This could reduce the need for separate vendor contracts, lower data integration costs, and improve data quality by eliminating reconciliation steps between disparate systems. However, sponsors should also evaluate whether the combined platform limits their flexibility to choose best-in-class point solutions for specific therapeutic areas.
Who were the financial and legal advisors on the deal?
Ropes & Gray advised Signant Health on the acquisition. Genstar Capital, the private equity firm backing Signant Health, financed the transaction. Archimed, the seller, had acquired Ametris (then ActiGraph) in a prior deal and oversaw its growth before the sale to Signant.
What does this mean for the DCT and eCOA vendor landscape?
The acquisition accelerates consolidation in the clinical trial technology market. Signant Health now offers a more comprehensive suite that competes directly with integrated platforms from Medidata and Clario. Smaller eCOA and digital health vendors may face pressure to either build or buy sensor capabilities to remain competitive. Pharma procurement teams should expect renewed contract negotiations as vendors jockey for position.
What to watch next
BD teams should track three things in the coming quarters. First, how Signant Health integrates Ametris's sensor validation data into its own regulatory submission packages—success here could set a precedent for digital endpoint acceptance. Second, whether the combined entity launches bundled pricing that undercuts standalone eCOA or sensor vendors, potentially triggering a price war in the DCT tools market. Third, whether Genstar Capital uses this acquisition as a platform for further roll-ups in the clinical trial technology space, snapping up analytics or RWE companies to broaden the offering.
The deal also has implications for the EMA's evolving framework for digital endpoints. As European regulators push for more objective measures in pivotal trials, a vendor that can deliver both patient-reported and sensor-derived data in a standardized format may hold a significant advantage in winning multi-regional study contracts.
Related coverage
Stay Updated on Pharma News
Get the latest drug approvals, clinical trials, and regulatory updates delivered to your inbox.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
